Dr Reddys Laboratories (RDY) Finished Goods (2009 - 2017)

Dr Reddys Laboratories (RDY) posted Finished Goods of $165.1 million for Q4 2017, down 2.6% on a QoQ basis from $169.5 million in Q3 2017.

Analysis

Dr Reddys Laboratories (RDY) Finished Goods (2009 - 2017) Analysis & Trends

Dr Reddys Laboratories has reported Finished Goods for 3 years, with the latest figure at $165.1 million in Q4 2017.

On a quarterly basis, Finished Goods changed N/A year-over-year to $165.1 million in Q4 2017; TTM through Dec 2017 was $165.1 million, a N/A change from a year earlier, with the FY2017 full-year figure at $184.6 million, changed N/A from the prior year.
Finished Goods was $165.1 million for Q4 2017 at Dr Reddys Laboratories, down from $169.5 million in the prior quarter.
The five-year high for Finished Goods was $184.8 million in Q1 2017, with the low at $155.9 million in Q1 2014.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	42.53 Bn	38.88 Bn	2.15 Bn
2	Viatris	19.14 Bn	18.25 Bn	1.46 Bn
3	Dr Reddys Laboratories	9.86 Bn	9.69 Bn	396.53 Mn
4	Amneal Pharmaceuticals	5.45 Bn	5.33 Bn	334.51 Mn
5	Bausch Health Companies	2.33 Bn	492.63 Mn	2.10 Bn
6	Alvotech	1.51 Bn	1.36 Bn	2.56 Mn
7	Ani Pharmaceuticals	1.48 Bn	1.12 Bn	165.89 Mn
8	Amphastar Pharmaceuticals	992.90 Mn	702.78 Mn	93.47 Mn
9	Fennec Pharmaceuticals	400.20 Mn	358.95 Mn	17.15 Mn
10	RedHill Biopharma	178.79 Mn	178.79 Mn	-

Historic Data

Download Data